Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2005-12-27 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2005
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It reports clinical trial results from a Phase 2 study of HepeX-B licensed to Cubist Pharmaceuticals. The content is primarily a press release announcing clinical trial data and related corporate updates, not a financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The document is about clinical trial results and corporate news rather than financial performance or governance changes. Form 6-K filings typically serve as regulatory filings to disclose material information by foreign private issuers. Therefore, this document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not meet criteria for other specific categories such as Annual Report, Earnings Release, or Management Reports.
2005-12-27 English
Immediate report on other matter
Regulatory Filings Classification · 90% confidence The document is a press release reporting results from a Phase 2 clinical study of a pharmaceutical product (HepeX-B) licensed to Cubist Pharmaceuticals. It includes detailed clinical trial data, discussion of manufacturing changes, and future regulatory plans with the FDA. The content is focused on clinical trial results and product development updates rather than financial results or regulatory filings. It is not an earnings release, annual report, or regulatory filing. It is a corporate announcement of clinical trial results, which does not fit into categories like M&A, capital updates, or governance. Given the nature of the document as a clinical trial results announcement, the closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement or corporate update that does not fit other specific categories. The document length (6576 characters) and detailed content confirm it is not a brief announcement or a report publication notice. Confidence is high due to clear clinical trial result reporting and absence of financial or governance data.
2005-12-22 Hebrew (modern)
Immediate report on other matter
Report Publication Announcement Classification · 98% confidence The document is very short (1702 characters) and appears to be a regulatory filing cover page or summary, indicated by the presence of the Israel Securities Authority and Tel Aviv Stock Exchange headers, a date of transmission (22/12/2005), and a reference number. Crucially, it contains the line: "Attached file *26-05Cubist_Reports_Ph2_Results_HepB_22Dec05_isa.pdf*". This structure—a brief announcement stating that a specific report is attached or published—fits the definition of a Report Publication Announcement (RPA) according to Rule 2 (The 'MENU VS MEAL' Rule). It is not the full report itself (like ER or IR), but the notification of its release.
2005-12-22 English
Regulatory Filings 2005
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It contains multiple press releases and announcements about clinical trial initiations, data presentations, management negotiations, and operational updates. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The content is primarily corporate announcements and updates rather than detailed financial or governance reports. It is not a transcript, audit report, or capital update. The document is a regulatory filing providing ongoing information about the company to the SEC and investors, consistent with the purpose of Form 6-K filings. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2005-12-20 English
Immediate report on other matter
Regulatory Filings Classification · 95% confidence The document is a press release dated December 16, 2005, announcing a reduction in workforce and a refocusing of the company's operations towards specific drug development programs. It contains no financial statements, no detailed financial data, no regulatory form references, and no mention of shareholder votes or meetings. The content is an operational update rather than a financial report or regulatory filing. The document length is 3226 characters, which is relatively short and typical for a press release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement about business strategy and operational changes, which is best classified as a general Regulatory Filing (RNS) since it does not fit other specific categories.
2005-12-18 Hebrew (modern)
Immediate report on other matter
Regulatory Filings Classification · 95% confidence The document is very short (1655 characters) and contains the header "Immediate report on other matter". Crucially, it explicitly states: "Attached file *25-05Update_on_Clinical_Programs_and_Planned_Operations_16Dec05_isa.pdf*". This structure—a brief announcement referencing an attached or linked document—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), according to Rule 2 (The 'Menu vs Meal' Rule). Since the content is an 'Immediate report on other matter' and not a standard financial report (like 10-K, IR, ER), and it announces the publication of an update, RPA is the most appropriate classification for announcing the release of a specific document, although RNS is also a strong candidate for general regulatory disclosures. Given the context of announcing a specific update document, RPA is chosen over the broader RNS.
2005-12-18 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.